Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer.

Milene Volpato Michele Cummings Abeer M Shaaban Balkees Abderrahman Mark A HullPhilipp Y MaximovBradley M BroomReiner HoppePing FanHiltrud B Brauch V Craig Jordan Valerie Speirs

Published in: Exploration of targeted anti-tumor therapy (2020)

HPGD downregulation in breast cancer is associated with reduced response to TAM therapy via PGE2-EP4 signalling and decreases patient survival. The data offer a potential target to develop combination therapies that may overcome acquired tamoxifen resistance.

Keyphrases

positive breast cancer
poor prognosis
long non coding rna
cell proliferation
estrogen receptor
signaling pathway
breast cancer cells
electronic health record
case report
big data
machine learning
endoplasmic reticulum
mesenchymal stem cells
cell therapy
human health
climate change
breast cancer risk